2011;6(10):236473 Tian B, Deng Y, Cai Y, Han M, Xu G
Once session is completed, IV drip will be removed by the doctor
Safety data from trials In a paper summarizing 6 randomized, double-blind, placebo-controlled human trials, AOD 9604 did not significantly affect IGF-1 levels, did not impair glucose tolerance, and no serious adverse events (SAEs) were attributed to AOD 9604
Key Benefits Reduces visceral fat by ~20% within 26 weeks Lowers liver fat by ~4.9% Decreases triglycerides by ~25% Increases IGF-1 levels by ~117 ng/mL Improves insulin sensitivity and reduces waist circumference Mechanism of Action Tesamorelin mimics your bodys natural GHRH, stimulating the anterior pituitary to release GH in pulses
Editorial refresh Practical 2026 note for Best Bpc Best Bpc now carries extra 2026 context around semaglutide, tirzepatide, BPC-157, cash-pay pricing, safety signals, best, because those are the subtopics readers tend to compare before they trust a medical or wellness recommendation
